Leqvio Approved as Adjunct Therapy to Lower Cholesterol
December 22, 2021FDA Approves Tascenso ODT to Treat Multiple Sclerosis in Children
December 23, 2021December 22, 2021 – The U.S. FDA has approved a new indication for Cosentyx® (secukinumab – Novartis) to treat active enthesitis-related arthritis (ERA) in individuals who are at least four years old. The agency has also expanded the drug's indication for treatment of active psoriatic arthritis (PsA) to include individuals at least two years of age. Previously, Cosentyx was only approved to treat PsA in adults.
- Cosentyx is the first biologic FDA approved to treat ERA, a rare type of juvenile idiopathic arthritis.
- Originally FDA approved in 2015, Cosentyx is also indicated to treat plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
- Recommended dosing for pediatric patients is based on weight, with injections given once weekly for the first five weeks and then once every four weeks thereafter. Cosentyx is a subcutaneous injection that can be administered at home once an individual has been instructed in proper technique by a healthcare provider.